![Maria del Pilar Matji de Arroquia](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Maria del Pilar Matji de Arroquia
Director/Miembro de la Junta en Universal Diagnostics SA .
Cargos activos de Maria del Pilar Matji de Arroquia
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Universal Diagnostics SA
![]() Universal Diagnostics SA Electronic Equipment/InstrumentsElectronic Technology Universal Diagnostics SL is a bioinformatics and multi-omics company based in Seville, Spain. The Spanish company's mission is to transform cancer into a curable disease by developing blood tests that detect cancer in its earliest stages. The company's first single-draw blood test, Signal-C, accurately detects colorectal cancer with a sensitivity rate of 92%% and specificity rate of 97%%, with extraordinary accuracy for earlier stages (89%%/97%%). The company is developing Signal-X™, a multi-cancer platform able to detect various types of high-burden cancers with high sensitivity and tissue-of-origin specificity. With its multi-omics + computational biology + machine learning approach, the company is cracking the code to "true" early cancer detection, having identified the specific cfdna sequence regions that capture cancer's earliest signal with +90%% accuracy. The company was founded by Marko Bitenc and Juan Martínez Barea, with Juan Martínez Barea serving as the CEO since incorporation. | Director/Miembro de la Junta | - | - |
Historial de carrera de Maria del Pilar Matji de Arroquia
Estadísticas
Internacional
España | 2 |
Operativa
Director/Board Member | 1 |
Sectorial
Electronic Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Universal Diagnostics SA
![]() Universal Diagnostics SA Electronic Equipment/InstrumentsElectronic Technology Universal Diagnostics SL is a bioinformatics and multi-omics company based in Seville, Spain. The Spanish company's mission is to transform cancer into a curable disease by developing blood tests that detect cancer in its earliest stages. The company's first single-draw blood test, Signal-C, accurately detects colorectal cancer with a sensitivity rate of 92%% and specificity rate of 97%%, with extraordinary accuracy for earlier stages (89%%/97%%). The company is developing Signal-X™, a multi-cancer platform able to detect various types of high-burden cancers with high sensitivity and tissue-of-origin specificity. With its multi-omics + computational biology + machine learning approach, the company is cracking the code to "true" early cancer detection, having identified the specific cfdna sequence regions that capture cancer's earliest signal with +90%% accuracy. The company was founded by Marko Bitenc and Juan Martínez Barea, with Juan Martínez Barea serving as the CEO since incorporation. | Electronic Technology |